Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Despite the rapidly increasing prevalence of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetes (T2D), few treatment modalities are currently available. We investigated the hepatic effects of the novel thiazolidinedione (TZDs), lobeglitazone (Duvie) in T2D patients with NAFLD. We recruited drug-naïve or metformin-treated T2D patients with NAFLD to conduct a multicenter, prospective, open-label, exploratory clinical trial. Transient liver elastography (Fibroscan®; Echosens, Paris, France) with controlled attenuation parameter (CAP) was used to non-invasively quantify hepatic fat contents. Fifty patients with CAP values above 250 dB/m were treated once daily with 0.5 mg lobeglitazone for 24 weeks. The primary endpoint was a decline in CAP values, and secondary endpoints included changes in components of glycemic, lipid, and liver profiles. Lobeglitazone-treated patients showed significantly decreased CAP values (313.4 dB/m at baseline vs. 297.8 dB/m at 24 weeks; P = 0.016), regardless of glycemic control. Lobeglitazone improved HbA(1C) values (7.41% [57.5 mM] vs. 6.56% [48.2 mM]; P < 0.001), as well as the lipid and liver profiles of the treated patients. Moreover, multivariable linear regression analysis showed that hepatic fat reduction by lobeglitazone was independently associated with baseline values of CAP, liver stiffness, and liver enzymes, and metformin use. Lobeglitazone treatment reduced intrahepatic fat content, as assessed by transient liver elastography, and improved glycemic, liver, and lipid profiles in T2D patients with NAFLD. Further randomized controlled trials using liver histology as an end point are necessary to evaluate the efficacy of lobeglitazone for NAFLD treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 1×
“Several clinical studies have investigated the effects of antidiabetic TZDs on NAFLD (21-25).”
BackgroundA placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · cited 3×
“Several clinical studies have investigated the effects of antidiabetic TZDs on NAFLD (21-25).”
BackgroundResultAithal, G. P., Thomas, J. A., Kaye, P. V., Lawson, A., Ryder, S. D., Spendlove, I., Austin, A. S., Freeman, J. G., Morgan, L., & Webber, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.047 · Cited by 721 · cited 3×
“Similar to previous studies (22,25), we also observed greater reductions in the ALT levels of responders, compared with those observed in non-responders, following treatment.”
BackgroundResultRatziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann–Heurtier, A., Serfaty, L., Podevin, P., Lacorte, J., Bernhardt, C., Bruckert, E., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.078 · Cited by 625 · cited 6×
“Although most previous trials with TZDs did not analyze predictors of responsiveness, a trial with rosiglitazone showed that responders have lower baseline γGTP levels and higher baseline amounts of steatosis than non-responders (22), which is consistent with our findings.”
BackgroundResultInfluentialSong, Y. M., Lee, Y.-H., Kim, J.-W., Ham, D.-S., Kang, E.-S., Cha, B. S., Lee, H. C., & Lee, B.-W. (2015) · Autophagy · doi:10.4161/15548627.2014.984271 · Cited by 332
Self-citationMetformin restores parkin-mediated mitophagy, suppressed by cytosolic p53
Song, Y., Lee, W., Lee, Y.-H., Kang, E., Cha, B.-S., & Lee, B.-W. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17010122 · Cited by 98 · cited 1×
“For example, lobeglitazone may play a role in decreasing the availability of plasma fatty acids arising from adipose tissue through abated lipolysis and the positive distribution of fat mass; on the other hand, metformin may activate either fatty acid oxidation or lipophagy, as well as mitophagy, via upregulation of t…”
BackgroundSelf-citation
Research works printed but not linked: 29
- Wang, 2011, Lancet, 378, 815, 10.1016/S0140-6736(11)60814-3 · DOI · Paper page
- Yoo, 2015, Diabetes Metab J, 39, 10, 10.4093/dmj.2015.39.1.10 · DOI · Paper page
- Park, 2016, J Korean Med Sci, 31, 410, 10.3346/jkms.2016.31.3.410 · DOI
- Lee, 2014, PLoS One, 9, e107584, 10.1371/journal.pone.0107584 · DOI · Paper page
- Chalasani, 2012, Hepatology, 55, 2005, 10.1002/hep.25762 · DOI · Paper page
- Williams, 2011, Gastroenterology, 140, 124, 10.1053/j.gastro.2010.09.038 · DOI · Paper page
- Kim, 2014, J Clin Endocrinol Metab, 99, 1879, 10.1210/jc.2013-4133 · DOI
- Harrison, 2008, Gut, 57, 1441, 10.1136/gut.2007.146019 · DOI · Paper page
- Chon, 2016, Yonsei Med J, 57, 885, 10.3349/ymj.2016.57.4.885 · DOI
- Kim, 2013, Endocrinol Metab (Seoul), 28, 280, 10.3803/EnM.2013.28.4.280 · DOI
- Sasso, 2010, Ultrasound Med Biol, 36, 1825, 10.1016/j.ultrasmedbio.2010.07.005 · DOI · Paper page
- de Lédinghen, 2014, J Hepatol, 60, 1026, 10.1016/j.jhep.2013.12.018 · DOI · Paper page
- Corzo, 2013, Diabetes Metab J, 37, 395, 10.4093/dmj.2013.37.6.395 · DOI
- Kim, 2011, Clin Ther, 33, 1819, 10.1016/j.clinthera.2011.09.023 · DOI
- Kim, 2014, PLoS One, 9, e92843, 10.1371/journal.pone.0092843 · DOI · Paper page
- Jin, 2015, Diabetes Obes Metab, 17, 599, 10.1111/dom.12435 · DOI
- Kim, 2015, Diabetes Res Clin Pract, 110, e27, 10.1016/j.diabres.2015.09.009 · DOI
- Chon, 2014, Liver Int, 34, 102, 10.1111/liv.12282 · DOI · Paper page
- Claridge, 2011, Lancet, 377, 2179, 10.1016/S0140-6736(11)60962-8 · DOI
- Arab, 2014, World J Gastroenterol, 20, 12182, 10.3748/wjg.v20.i34.12182 · DOI
- Sanyal, 2004, Clin Gastroenterol Hepatol, 2, 1107, 10.1016/S1542-3565(04)00457-4 · DOI · Paper page
- Musso, 2010, Hepatology, 52, 79, 10.1002/hep.23623 · DOI · Paper page
- Lupșor-Platon, 2015, J Gastrointestin Liver Dis, 24, 35, 10.15403/jgld.2014.1121.mlp · DOI
- Shen, 2014, World J Gastroenterol, 20, 4702, 10.3748/wjg.v20.i16.4702 · DOI
- Masaki, 2013, Hepatol Res, 43, 1182, 10.1111/hepr.12094 · DOI
- de Lédinghen, 2016, J Gastroenterol Hepatol, 31, 848, 10.1111/jgh.13219 · DOI · Paper page
- Bi, 2014, Acta Diabetol, 51, 865, 10.1007/s00592-014-0638-3 · DOI
- Koenen, 2009, J Clin Endocrinol Metab, 94, 4453, 10.1210/jc.2009-0517 · DOI · Paper page
- Musso, 2012, Diabetologia, 55, 885, 10.1007/s00125-011-2446-4 · DOI · Paper page
Cited by
Shimizu, M., Suzuki, K., Kato, K., Jojima, T., Iijima, T., Murohisa, T., Iijima, M., Takekawa, H., Usui, I., Hiraishi, H., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13520 · Cited by 390
Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
Pafili, K., & Roden, M. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101122 · Cited by 330
Lipid alterations in chronic liver disease and liver cancer
Paul, B., Lewinska, M., & Andersen, J. B. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100479 · Cited by 308
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Cheng, H. S., Tan, W. R., Low, Z. S., Marvalim, C., Lee, J. Y. H., & Tan, N. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205055 · Cited by 264
Insulin resistance and insulin sensitizing agents
Mastrototaro, L., & Roden, M. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154892 · Cited by 254
Luci, C., Bourinet, M., Leclère, P. S., Anty, R., & Gual, P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.597648 · Cited by 195
Chehrehgosha, H., Sohrabi, M. R., Ismail-Beigi, F., Malek, M., Reza Babaei, M., Zamani, F., Ajdarkosh, H., Khoonsari, M., Fallah, A. E., & Khamseh, M. E. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01011-3 · Cited by 173
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
“Lobeglitazone PPAR γ PO Phase III Yes No NA NA Yes [77]”
Background
Metadata
- Authors
- Lee, Y.-H., Kim, J. H., Kim, S. R., Jin, H. Y., Rhee, E.-J., Cho, Y. M., & Lee, B.-W.
- Venue
- Journal of Korean Medical Science
- Publisher
- XMLink
- Published
- 2017
- Volume
- 32
- Issue
- 1
- Pages
- 60
- ISSN
- 1011-8934 (ISSN-L)
- 1598-6357
- OpenAlex
- W2555612317
- Cited by
- 104
- References
- 6
- FWCI
- 6.54
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
- Funders
- Chong Keun Dang, Pharmaceutical Co.
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.